What are the side effects for AIDS/HIV
Some symptoms initially include fever, headache, tiredness, and enlarged lymph nodes. The other main symptom is a severely weakened immune system, which can lead to other diseases and illness. ChaCha on! [ Source: http://www.chacha.com/question/what-are-the-side-effects-for-aids%26%2347%3Bhiv ]
More Answers to “What are the side effects for AIDS/HIV“
- What are the side effects for AIDS/HIV
- Some symptoms initially include fever, headache, tiredness, and enlarged lymph nodes. The other main symptom is a severely weakened immune system, which can lead to other diseases and illness. ChaCha on!
- How to Manage AIDS HIV Treatment Side Effects
- ･ 1 Prepare and plan ahead. You should know what to expect when it comes to the side effects of HIV and… ･ 2 Communicate with your doctor. You are seldom so limited in your options that you cannot tailor your… ･ 3 Work with your doctor …
- What are the effects of HIV/AIDS?
- HIV/AIDS Symptoms As the infection progresses, people with HIV grow increasingly susceptible to illnesses and infection that don’t normally affect the healthy population. Even though many of these illnesses can easily be treated, those with…
Related Questions Answered on Y!Answers
- what are the best combination of medications taken with least amount of side effects for aids/HIV?
- A: all combos have their side effects, HAART is the way to go these days, your ID doctor should talk about the best combo he/she has, good luck
- what medications should an AIDS/HIV patient Take?
- Q: i want to know what 5 possible medications a patient with AIDS may be on. and please state how each medication may help the patient, its action, usual dosage, common side effects, and possible adverse reactions to watch out for PLEASEEEEEEEE HELPPPPPPP.
- A: …there are now 5 dif classes of HIV drugs…here they are as follows;HIV Drug Guide IntroductionA Brief Description of the Drug Classes and How They WorkBy Joel Gallant, M.D., M.P.H.March/April 2009Antiretroviral drugs are classified based on the stage of the HIV life cycle they target. In the end, they all do the same thing — prevent the virus from replicating — but they do it in different ways. 2007 brought us two new drug classes: the CCR5 antagonists (a type of entry inhibitor) and the integrase inhibitors, so there are now six classes to choose from (if you count CCR5 antagonists and fusion inhibitors, both types of entry inhibitors, as separate classes). With few exceptions, most antiretroviral regimens include drugs from at least two classes, because attacking the virus with drugs that work in different ways is thought to help prevent resistance. The traditional combinations, especially for initial therapy, have been combinations of nucleoside analog reverse transcriptase inhibitors (NRTIs) plus either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI), but with more classes, we’ll begin to see the emergence of new approaches and more options for therapy.Nucleoside Analog Reverse Transcriptase Inhibitors (NRTIs) or “Nukes”Nucleoside analogs, or “nukes,” work by preventing reverse transcriptase, a viral enzyme, from turning HIV RNA into DNA. The nukes mimic the normal building blocks of DNA, but when they get pulled into the growing DNA chain, they screw up the process and keep the chain from being completed. The nukes were the only drugs we had until 1996, and they’ve been components of just about every drug regimen since the approval of Retrovir (AZT) in the mid-80’s. Most ART combinations today consist of a combination of at least two nucleosides (the “backbone”) plus one or more drugs from a different class. The popularity of nukes took a hit when we learned they caused lipoatrophy, which we’d been blaming on protease inhibitors. But it turned out that lipoatrophy (and other related toxicities) were caused primarily by the thymidine analogs (Zerit and Retrovir) but not by Epivir, Emtriva, Ziagen or Viread. As a result, we’re not as afraid of nukes as we used to be.Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or “Non-Nukes”The NNRTIs, or “non-nukes,” are powerful, convenient drugs with little long-term toxicity. Side effects occur early on, usually in the first few weeks, and include nervous system side effects with Sustiva, liver toxicity with Viramune, and rash with both. In contrast to boosted PIs, resistance to NNRTIs can occur easily and quickly if the viral load isn’t suppressed. These are great drugs for people who are good at taking meds and want a simple combination, but they’re not the best choice for those who start and stop meds frequently.Protease Inhibitors (PIs)AdvertisementThe PIs are the drugs that changed everything. It was the combination of NRTIs plus PIs that first allowed us to completely suppress HIV viral load. Suddenly, we could do more than just temporarily boost the CD4 count for a year or two. HIV infection quickly went from being a progressive fatal disease to one that was chronic and manageable. Management wasn’t easy, though. The early PIs were hard drugs to take: lots of pills, lots of doses, and lots of side effects and long-term toxicity. That’s changed, in part because of ritonavir “boosting.” Almost all PIs are now taken with a low dose of ritonavir (Norvir), which boosts drug levels and simplifies dosing (see “Norvir”). New PIs and new formulations of old PIs have also expanded options and have made PIs a lot easier to take than they used to be. Still, it’s important to be aware of PI toxicity. To varying degrees, the PIs can raise lipids (cholesterol and triglycerides), can cause insulin resistance (which can lead to diabetes), and may cause body shape changes, specifically fat accumulation. PIs can sometimes cause diarrhea or loose stools that typically disappear with fiber supplements like Metamucil, Fibercon, or Citrucel. (Don’t be put off by the word “laxative” on the bottle — fiber helps whether you’ve got diarrhea or constipation.)Entry InhibitorsEntry inhibitors block entry of the virus into the CD4 cell. There are several stages of viral entry. The first is attachment of the virus to the CD4 receptor. There aren’t any attachment inhibitors available yet, but this is a potential target for drug development. The next step is binding of the virus to a coreceptor (either CCR5 or CXCR4). In 2007, the first CCR5 antagonist, Selzentry, was approved by the FDA. The final step involves fusion of the envelope of the virus with the membrane of the CD4 cell, a step blocked by Fuzeon, a fusion inhibitor. For more information, see the Selzentry and Fuzeon drug pages.Integrase InhibitorIntegrase inhibitors, the newest class of drugs, block the insertion of HIV DNA into hu